title: [HAI chemotherapy for liver metastases of colorectal cancer].
abstract: We evaluated the effect of hepatic arterial infusion(HAI)chemotherapy for liver metastases from colorectal cancer. A total of 65 patients received HAI chemotherapy. The chemotherapy regimen consisted of weekly 5-FU (1, 500 mg/body) or 5-FU (400 mg/mm2) and l-LV (200mg/mm2). The survival and response rates were assessed according to RECIST. Median survival time with HAI chemotherapy was 13. 5 months, 5-year survival rate 8% and response rates 55%. There was no evidence of myelosuppression, and HAI could be continued for a long time even for poor PS patients. There were no differences in survival time between synchronous, metachronous and postoperative metachronous liver metastases. In the patients who underwent curative hepatectomy after HAI chemotherapy, the 5-year survival rate was 21%, which was better than in patients with HAI chemotherapy alone. HAI chemotherapy could thus be an option for unresectable liver metastases, which could be well tolerated.
authors.affiliation: Department of Surgery, Fujita Health University School of Medicine.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsuoka
authors.forename: Kotaro
authors.initials: K
authors.lastname: Maeda
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Hanai
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Kouji
authors.initials: K
authors.lastname: Masumori
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Koide
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Katsuno
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Agata
authors.forename: Tomohito
authors.initials: T
authors.lastname: Noro
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Honda
authors.forename: Miho
authors.initials: M
authors.lastname: Shiota
authors.forename: Shinji
authors.initials: S
authors.lastname: Ozeki
authors.forename: Kouhei
authors.initials: K
authors.lastname: Hatta
authors.forename: Zenichi
authors.initials: Z
authors.lastname: Morise
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugioka
authors.forename: Hideki
authors.initials: H
authors.lastname: Ota
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil